XW013F5Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5

New Technology›Anatomical Regions›Introduction
  • Billable / Specific Code
ICD-10-PCS XW013F5
CMS Source: FY 2027 ICD-10-PCS dataset. Effective Oct 1, 2026 – Sep 30, 2027.FacebookXLinkedInPrint

XW013F5 is a billable ICD-10-PCS procedure code for Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Potential COVID-19 therapies.

Code Identity

ICD-10-PCS Code
XW013F5
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
Short Description
Introduce New Tech Therap in Subcu, Perc, New Tech 5
Parent Code
XW0

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation0Introduction
4BodyPart1Subcutaneous Tissue
5Approach3Percutaneous
6Device/Substance/TechnologyFOther New Technology Therapeutic Substance
7Qualifier5New Technology Group 5

In the ICD-10-PCS Alphabetic Index

These FY 2027 ICD-10-PCS Alphabetic Index entries lead to this code:

STELARA(R)
Anatomy or device term that leads here
Iloprost
Leads to this code's table
Sarilumab
Leads to this code's table
Posoleucel
Leads to this code's table
Rezafungin
Leads to this code's table
Treosulfan
Leads to this code's table
Baricitinib
Leads to this code's table
Sabizabulin
Leads to this code's table
Tocilizumab
Leads to this code's table
Ustekinumab
Anatomy or device term that leads here
Caplacizumab
Leads to this code's table
COVID-19 Vaccine
Leads to this code's table
Inebilizumab-cdon
Leads to this code's table
Sulbactam-Durlobactam
Leads to this code's table
CD24Fc Immunomodulator
Leads to this code's table

Browse the full ICD-10-PCS Alphabetic Index →

Clinical Classification (CCSR)

AHRQ groups this procedure code into these clinical categories.

ADM019
Potential COVID-19 therapies
Clinical domain: Administration of Therapeutic Substances

Code History

Replaces previously assigned code(s):
  • 3E013GC — Introduction of Oth Therap Subst into Subcu, Perc Approach
Replaced in the FY 2027 code set by:
  • XW013G6 — Introduce of REGN-COV2 into Subcu, Perc Approach, New Tech 6
  • XW013H6 — Introduce Monclon Antib in Subcu, Perc, New Tech 6
  • XW013K6 — Introduce Leronlimab in Subcu, Perc, New Tech 6

Similar Procedure Codes

Questions About XW013F5

Is XW013F5 a billable code?

Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 on inpatient claims from October 1, 2026 through September 30, 2027.

What do the characters in XW013F5 mean?

The code breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 1 is the BodyPart (Subcutaneous Tissue); the 5th character 3 is the Approach (Percutaneous); the 6th character F is the Device/Substance/Technology (Other New Technology Therapeutic Substance); the 7th character 5 is the Qualifier (New Technology Group 5).